{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T19:14:05Z","timestamp":1773947645364,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["2022ELYS5F"],"award-info":[{"award-number":["2022ELYS5F"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008480","name":"Arkansas Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117735","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T07:38:42Z","timestamp":1747121922000},"page":"117735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor"],"prefix":"10.1016","volume":"294","author":[{"given":"Phuc","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marialuisa","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Brescia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Federico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naresh","family":"Gunaganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minmin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baha'a","family":"Jabali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan","family":"Frett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Carlomagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9212-2010","authenticated-orcid":false,"given":"Hong-yu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117735_bib1","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1083\/jcb.200604032","article-title":"The chromosomal passenger complex: guiding Aurora-B through mitosis","volume":"173","author":"Vader","year":"2006","journal-title":"JCB (J. Cell Biol.)"},{"key":"10.1016\/j.ejmech.2025.117735_bib2","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1247\/csf.26.653","article-title":"Advances in cytokinesis research. Role of chromosomal passenger complex in chromosome segregation and cytokinesis","volume":"26","author":"Terada","year":"2001","journal-title":"Cell Struct. Funct."},{"key":"10.1016\/j.ejmech.2025.117735_bib3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00428-014-1577-7","article-title":"BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma","volume":"464","author":"Davidson","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejmech.2025.117735_bib4","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-009-0838-3","article-title":"Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients","volume":"455","author":"Chen","year":"2009","journal-title":"Virchows Arch."},{"key":"10.1016\/j.ejmech.2025.117735_bib5","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/ijc.33137","article-title":"Characterization of a dual inhibitor for treatment of pancreatic ductal adenocarcinoma","volume":"147","author":"Zhang","year":"2020","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.117735_bib6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1476-4598-9-42","article-title":"Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer","volume":"9","author":"Gully","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.117735_bib7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s00595-013-0581-x","article-title":"Contribution of Aurora-A and -B expression to DNA aneuploidy in gastric cancers","volume":"44","author":"Honma","year":"2014","journal-title":"Surg. Today"},{"key":"10.1016\/j.ejmech.2025.117735_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.humpath.2014.11.016","article-title":"Aurora kinase A gene copy number is associated with the malignant transformation of colorectal adenomas but not with the serrated neoplasia progression","volume":"46","author":"Casorzo","year":"2015","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.ejmech.2025.117735_bib9","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/pros.20345","article-title":"Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation","volume":"66","author":"Chieffi","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2025.117735_bib10","doi-asserted-by":"crossref","first-page":"4996","DOI":"10.1158\/0008-5472.CAN-05-2796","article-title":"Targeting Aurora kinases for the treatment of prostate cancer","volume":"66","author":"Lee","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117735_bib11","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.3390\/cancers12113371","article-title":"Promising therapy in lung cancer: spotlight on Aurora kinases","volume":"12","author":"Galetta","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.117735_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1026020","article-title":"Unweaving the mitotic spindle: a focus on Aurora kinase inhibitors in lung cancer","volume":"12","author":"Stefani","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117735_bib13","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/leu.2012.256","article-title":"Aurora kinases in childhood acute leukemia: the promise of aurora B as therapeutic target","volume":"27","author":"Hartsink-Segers","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117735_bib14","first-page":"482","article-title":"A new prognostic marker and therapeutic target in cancer","volume":"18","author":"Portella","year":"2011","journal-title":"Comput. Mater. Continua (CMC)"},{"key":"10.1016\/j.ejmech.2025.117735_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117735_bib16","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/molecules26071981","article-title":"Aurora kinase B inhibition: a potential therapeutic strategy for cancer","volume":"26","author":"Borah","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117735_bib17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1053\/j.seminoncol.2015.09.022","article-title":"Aurora Kinase inhibitors in oncology clinical trials: current state of the progress","volume":"42","author":"Falchook","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117735_bib18","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1158\/1535-7163.MCT-16-0066","article-title":"Pharmacological profile of BI 847325, an orally bioavailable, ATP-competitive inhibitor of MEK and Aurora kinases","volume":"15","author":"Sini","year":"2016","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117735_bib19","doi-asserted-by":"crossref","first-page":"3385","DOI":"10.3390\/molecules28083385","article-title":"Aurora B inhibitors as cancer therapeutics","volume":"28","author":"Kovacs","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.117735_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00280-012-1939-2","article-title":"Phase I study of the Aurora B kinase inhibitor barasertib (AZD1152) to assess the pharmacokinetics, metabolism and excretion in patients with acute myeloid leukemia","volume":"70","author":"Dennis","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117735_bib21","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1535-7163.MCT-18-0577","article-title":"Modeling dose and schedule effects of AZD2811 nanoparticles targeting Aurora B Kinase for treatment of diffuse large B-cell lymphoma","volume":"18","author":"Floc\u2019h","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117735_bib23","first-page":"5094","article-title":"Phase I pharmacokinetic and pharmacodynamic study of the Aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors","volume":"27","author":"Steeghs","year":"2009","journal-title":"J. Clin. Orthod."},{"key":"10.1016\/j.ejmech.2025.117735_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112589","article-title":"Discovery of SP-96, the first non-ATP-competitive Aurora kinase B inhibitor, for reduced myelosuppression","volume":"203","author":"Lakkaniga","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117735_bib25","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1016\/S0040-4039(01)95429-2","article-title":"A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenylboranes with 1-alkenyl or 1-alkynyl halides","volume":"20","author":"Miyaura","year":"1979","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.117735_bib26","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acs.jmedchem.8b01594","article-title":"Discovery of N -(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a potent FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutant selective inhibitor for acute myeloid leukemia","volume":"62","author":"Liang","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117735_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/325549a0","article-title":"Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)","volume":"325","author":"Roussel","year":"1987","journal-title":"Nature"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:11:25Z","timestamp":1765602685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":26,"alternative-id":["S0223523425005008"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117735","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitor","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117735"}}